Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2017 09:02 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease

Issued claims include therapeutic protein, gene therapy and cell therapy applicationsPatent extends MANF Therapeutics' exclusivity for MANF treatment of Parkinson's disease in Japan into 2029 SAN...
December 14, 2017 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF

Data demonstrates MANF's role in modulating the immune microenvironment in the retina and its potential for treating retinal disordersPatent extends MANF Therapeutics' exclusivity for MANF and CDNF...
December 11, 2017 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes

Allowed claims include the treatment of Type 1 and Type 2 DiabetesOnce issued, patents extend exclusivity for MANF in the US into 2032 SAN FRANCISCO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Amarantus...
December 08, 2017 10:27 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID

Patents extend Eltoprazine Parkinson’s disease LID treatment exclusivity into 2033 SAN FRANCISCO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based...
December 05, 2017 07:45 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer's Disease and Parkinson's disease with Eltoprazine

SAN FRANCISCO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class...
November 13, 2015 08:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference

SAN FRANCISCO, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
October 29, 2015 09:58 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Issuance of Australian Patent No. 61/057,713 Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease

SAN FRANCISCO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
October 26, 2015 08:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs

SAN FRANCISCO, Oct. 26, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
October 22, 2015 09:15 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Submits Orphan Drug Designation Application to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia

SAN FRANCISCO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
October 19, 2015 08:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus to Present at BIO Investor Forum 2015

SAN FRANCISCO, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right